Rob Holt, University of Ottawa

Research

Access To Care Car-T Leukemia Point-Of-Care Biomanufacturing Car-T Cells Immunotherapy Scleroderma Systemic Sclerosis

Latest funding

Canadian-Made CD19 CAR-T Therapy for Refractory Systemic Sclerosis, from the Canadian Led Immunotherapies Collaborative (CLIC-03 Trial)
CIHR · 2025 · Principal investigator
$1,216,351
Paving The Way to a Canadian Standard of Care with CAR-T Cellular Therapy: Phase II Trial of CD19 CAR-T for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia (CLIC-01A)
CIHR · 2022 · Principal investigator
$3,216,843
Paving The Way to a Canadian Standard of Care with CAR-T Cellular Therapy: Phase II Trial of CD19 CAR-T for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia (CLIC-01A)
CIHR · 2022 · Principal investigator
$804,211

All 3 grants and awards

Canadian-Made CD19 CAR-T Therapy for Refractory Systemic Sclerosis, from the Canadian Led Immunotherapies Collaborative (CLIC-03 Trial)

Principal investigatorCIHR2025Project Grant

Principal investigators: Kekre, Natasha; Hay, Kevin A; Holt, Rob; Hudson, Marie; Maltez, Nancy

Keywords: Car-T Cells; Immunotherapy; Scleroderma; Systemic Sclerosis

$1,216,351

Paving The Way to a Canadian Standard of Care with CAR-T Cellular Therapy: Phase II Trial of CD19 CAR-T for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia (CLIC-01A)

Principal investigatorCIHR2022Operating Grant: Clinical Trials Projects

Principal investigators: Kekre, Natasha; Bredeson, Christopher; Hawrysh, Terry A; Fergusson, Dean A; Hay, Kevin A; Holt, Rob; Quizi, Jennifer L; Thavorn, Kednapa

Keywords: Access To Care; Car-T; Leukemia; Point-Of-Care Biomanufacturing

$3,216,843

Paving The Way to a Canadian Standard of Care with CAR-T Cellular Therapy: Phase II Trial of CD19 CAR-T for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia (CLIC-01A)

Principal investigatorCIHR2022Operating Grant: Clinical Trials Projects - Indirect Costs

Principal investigators: Kekre, Natasha; Bredeson, Christopher; Hawrysh, Terry A; Fergusson, Dean A; Hay, Kevin A; Holt, Rob; Quizi, Jennifer L; Thavorn, Kednapa

Keywords: Access To Care; Car-T; Leukemia; Point-Of-Care Biomanufacturing

$804,211

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Mention their CIHR grant from 2025

Subject: Prospective PhD student: Access To Care Dear Professor Holt, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. Your research on access to care connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Canadian-Made CD19 CAR-T Therapy for Refractory Systemic Sclerosis, from the Canadian Led Immunotherapies Collaborative (CLIC-03 Trial)" (2025), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]